Your browser doesn't support javascript.
loading
Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance.
Pietilä, Elina A; Gonzalez-Molina, Jordi; Moyano-Galceran, Lidia; Jamalzadeh, Sanaz; Zhang, Kaiyang; Lehtinen, Laura; Turunen, S Pauliina; Martins, Tomás A; Gultekin, Okan; Lamminen, Tarja; Kaipio, Katja; Joneborg, Ulrika; Hynninen, Johanna; Hietanen, Sakari; Grénman, Seija; Lehtonen, Rainer; Hautaniemi, Sampsa; Carpén, Olli; Carlson, Joseph W; Lehti, Kaisa.
Afiliação
  • Pietilä EA; Individualized Drug Therapy Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
  • Gonzalez-Molina J; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Moyano-Galceran L; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Jamalzadeh S; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Zhang K; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Lehtinen L; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Turunen SP; Research Center for Cancer, Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland.
  • Martins TA; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Gultekin O; Individualized Drug Therapy Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
  • Lamminen T; Department of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Kaipio K; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Joneborg U; Research Center for Cancer, Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland.
  • Hynninen J; Research Center for Cancer, Infections and Immunity, Institute of Biomedicine, University of Turku, Turku, Finland.
  • Hietanen S; Department of Women's and Children's Health, Division Obstetrics and Gynaecology, Karolinska Institutet, Stockholm, Sweden.
  • Grénman S; Department of Pelvic Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Lehtonen R; Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, Turku, Finland.
  • Hautaniemi S; Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, Turku, Finland.
  • Carpén O; Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku, Turku, Finland.
  • Carlson JW; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Lehti K; Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Nat Commun ; 12(1): 3904, 2021 06 23.
Article em En | MEDLINE | ID: mdl-34162871
Due to its dynamic nature, the evolution of cancer cell-extracellular matrix (ECM) crosstalk, critically affecting metastasis and treatment resistance, remains elusive. Our results show that platinum-chemotherapy itself enhances resistance by progressively changing the cancer cell-intrinsic adhesion signaling and cell-surrounding ECM. Examining ovarian high-grade serous carcinoma (HGSC) transcriptome and histology, we describe the fibrotic ECM heterogeneity at primary tumors and distinct metastatic sites, prior and after chemotherapy. Using cell models from systematic ECM screen to collagen-based 2D and 3D cultures, we demonstrate that both specific ECM substrates and stiffness increase resistance to platinum-mediated, apoptosis-inducing DNA damage via FAK and ß1 integrin-pMLC-YAP signaling. Among such substrates around metastatic HGSCs, COL6 was upregulated by chemotherapy and enhanced the resistance of relapse, but not treatment-naïve, HGSC organoids. These results identify matrix adhesion as an adaptive response, driving HGSC aggressiveness via co-evolving ECM composition and sensing, suggesting stromal and tumor strategies for ECM pathway targeting.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Female / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article